Welcome to our dedicated page for Bowen Acquisition news (Ticker: BOWN), a resource for investors and traders seeking the latest updates and insights on Bowen Acquisition stock.
Bowen Acquisition Corp (NASDAQ: BOWN) generates news primarily as a special purpose acquisition company (SPAC) in the financial services sector. As a blank check company formed to complete a business combination, its most significant announcements relate to its initial public offering, trust account funding, proposed merger transactions, and interactions with stock exchange regulators.
A key focus of BOWN news has been its agreement and plan of merger with Shenzhen Qianzhi BioTechnology Co. Ltd. and its parent entity. Press releases describe Qianzhi BioTech as a health and wellness focused biotech company based in Shenzhen, China, engaged in development, manufacturing and sales of plant-based and ozonated products for antibacterial, skincare, gynecological and andrological applications, as well as ozonated disinfectant products. Updates on this proposed business combination, including regulatory filings and shareholder approvals, are central to understanding BOWN’s strategic direction.
Another important stream of news concerns Bowen Acquisition Corp’s listing status on the Nasdaq Global Market. The company has disclosed receiving Nasdaq notifications of non-compliance with continued listing rules, delisting determination letters, trading halts, and the outcomes of hearings before Nasdaq panels. These items explain why and how Nasdaq applied its listing criteria, the conditions imposed for continued listing, and subsequent decisions to delist the securities when certain deadlines were not met.
Investors following BOWN news can expect coverage of: proposed and actual extensions of the deadline to complete a business combination; notifications of late filing of periodic reports; progress toward closing the merger with Shenzhen Qianzhi BioTechnology Co. Ltd.; and developments in the company’s appeals of Nasdaq’s delisting determinations. Monitoring this news flow helps readers understand both the status of the SPAC’s business combination efforts and the trading and regulatory context for BOWN and BOWNR securities over time.
Bowen Acquisition Corp (NASDAQ: BOWN), a special purpose acquisition company, received a delisting determination letter from Nasdaq on July 15, 2025, due to multiple listing requirement violations. The company failed to maintain: $50 million minimum market value of listed securities, 1.1 million publicly held shares, $15 million market value of publicly held shares, and 400 total shareholders.
BOWN has until July 22, 2025, to appeal the decision to a Nasdaq Hearings Panel. Without an appeal, trading will be suspended on July 24, 2025. The company intends to request a hearing and a trading suspension stay while pursuing its planned business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN) has received a non-compliance notification from NASDAQ on May 28, 2025, due to failing to submit its Q1 2025 Form 10-Q quarterly report. The company has until July 28, 2025 to submit a compliance plan to NASDAQ. If approved, NASDAQ may grant BOWN an extension of up to 180 calendar days (until November 17, 2025) to regain compliance. While this notification does not immediately affect BOWN's NASDAQ listing, there is no guarantee the company will successfully regain compliance with listing requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Bowen Acquisition (BOWN)?
What is the market cap of Bowen Acquisition (BOWN)?
